We aimed to evaluate the efficacy (short-term changes in surrogates of decongestion) and safety following the ambulatory administration of subcutaneous furosemide (SCF) in patients with WHF. Fifty-five ambulatory patients were treated with SCF administered by an elastomeric pump for at least 72 h. Surrogates of congestion were assessed at baseline, 72 h, and 30 days. Spot urinary sodium (uNa+) was assessed at baseline, 24-48-72 h, and 30 days. The median (IQI) of NT-proBNP and uNa+ at baseline was 5218 pg/mL (2856-10878) and 68±3 mmol/L, respectively. Following administration of SCF (median dose of 100 mg/daily), we found a sustained increase in uNa+ during the first 72 h of treatment compared to baseline, paralleled with evidence of decongestion at 72 h, and 30 days. No significant safety concerns were observed. SCF was an effective and safe diuretic strategy for outpatient congestion management.

Graphical abstract

中文翻译：

---

心力衰竭加重患者皮下输注非配方速尿的疗效和安全性：真实世界研究

我们旨在评估 WHF 患者皮下注射呋塞米 (SCF) 后的疗效（缓解充血替代物的短期变化）和安全性。55 名非卧床患者接受了由弹性泵管理的 SCF 治疗至少 72 小时。在基线、72 小时和 30 天评估充血替代物。在基线、24-48-72 小时和 30 天评估现场尿钠 (uNa+)。NT-proBNP 和 uNa+ 在基线时的中位数 (IQI) 分别为 5218 pg/mL (2856-10878) 和 68±3 mmol/L。在施用 SCF（中位剂量为 100 mg/天）后，我们发现与基线相比，在治疗的前 72 小时内 uNa+ 持续增加，同时在 72 小时和 30 天有缓解充血的证据。没有观察到重大的安全问题。

图形概要